PE20010212A1 - COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM - Google Patents
COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEMInfo
- Publication number
- PE20010212A1 PE20010212A1 PE2000000521A PE0005212000A PE20010212A1 PE 20010212 A1 PE20010212 A1 PE 20010212A1 PE 2000000521 A PE2000000521 A PE 2000000521A PE 0005212000 A PE0005212000 A PE 0005212000A PE 20010212 A1 PE20010212 A1 PE 20010212A1
- Authority
- PE
- Peru
- Prior art keywords
- peptide
- composition
- solubilize
- refers
- sufficient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 2
- -1 AMMONIUM HYDROXIDES Chemical class 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940037003 alum Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 229930182470 glycoside Natural products 0.000 abstract 1
- 229910000000 metal hydroxide Inorganic materials 0.000 abstract 1
- 150000004692 metal hydroxides Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE UNA SOLUCION ACUOSA DE POR LO MENOS 0,01 mg/ml DE PEPTIDO ß AMILOIDE (Aß), DE PREFERENCIA LA FORMA LARGA; Aß42; CONFORMACION ESPIRALADA; UN BUFFER QUE MANTIENE EL pH ALREDEDOR 8,5 A 12 O SUFICIENTE PARA SOLUBILIZAR DICHO PEPTIDO Aß DE PREFERENCIA AMINOACIDOS, SALES, ALCALINIZANTES ACEPTABLES, HIDROXIDOS DE METALES ALCALINOS E HIDROXIDOS DE AMONIO, ACIDOS ORGANICOS; ADYUVANTE INCOMPLETO DE FREUND, 3 DE O-ACIL MONOFOSFORIL LIPIDO A (MPL), GLICOSIDO TRITERPENICO (QS21) Y ALUMBRE; 10mM DE GLICINA; 20mM DE CITRATO DE SODIO; 5% DE SACAROSA; ENTRE 0,9%(m/v) Y 6%(m/v) DE UN AGENTE DE TONICIDAD; ENTRE 0,05%(m/v) Y 0,5%(m/v) DE UN TENSOACTIVO, ENTRE 0,1mM Y 1mM DE UN AGENTE QUELANTE. TAMBIEN SE REFIERE A UNA COMPOSICION LIOFILIZADA DEL PEPTIDO Aß EN DONDE DICHA SOLUCION SE MANTIENE A UN pH SUFICIENTE PARA SOLUBILIZAR EL PEPTIDO; LIOFILIZAR LA COMPOSICION CONGELADA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMERIT REFERS TO A COMPOSITION THAT INCLUDES AN AQUEOUS SOLUTION OF AT LEAST 0.01 mg / ml OF PEPTIDE ß AMYLOID (Aß), PREFERABLY THE LONG FORM; Aß42; SPIRAL CONFORMATION; A BUFFER THAT MAINTAINS THE pH AROUND 8.5 TO 12 OR SUFFICIENT TO SOLUBILIZE SAID Aß PEPTIDE OF PREFERENCE AMINO ACIDS, SALTS, ACCEPTABLE ALKALINIZERS, ALKALINE METAL HYDROXIDES AND AMMONIUM HYDROXIDES, ORGANIC ACIDS; FREUND'S INCOMPLETE ADJUVANT, 3-O-ACIL MONOPHOSPHORYL LIPID A (MPL), TRITERPENIC GLYCOSIDE (QS21) AND ALUM; 10mM GLYCINE; 20mM SODIUM CITRATE; 5% SACROSE; BETWEEN 0.9% (m / v) AND 6% (m / v) OF A TONICITY AGENT; BETWEEN 0.05% (m / v) AND 0.5% (m / v) OF A SURFACTANT, BETWEEN 0.1mM AND 1mM OF A CHELATING AGENT. IT ALSO REFERS TO A LYOPHILIZED COMPOSITION OF THE Aß PEPTIDE, WHERE SAID SOLUTION IS KEPT AT A SUFFICIENT pH TO SOLUBILIZE THE PEPTIDE; FREEZE THE FROZEN COMPOSITION. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13704799P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010212A1 true PE20010212A1 (en) | 2001-02-22 |
Family
ID=22475602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000521A PE20010212A1 (en) | 1999-06-01 | 2000-05-31 | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1181040A1 (en) |
| JP (1) | JP2003519620A (en) |
| KR (1) | KR20020016813A (en) |
| CN (1) | CN1353615A (en) |
| AR (1) | AR024558A1 (en) |
| AU (1) | AU5726100A (en) |
| BG (1) | BG106249A (en) |
| BR (1) | BR0011251A (en) |
| CA (1) | CA2374897A1 (en) |
| CZ (1) | CZ20014150A3 (en) |
| EE (1) | EE200100649A (en) |
| HK (1) | HK1045938A1 (en) |
| HR (1) | HRP20010901A2 (en) |
| IL (1) | IL146575A0 (en) |
| IS (1) | IS6182A (en) |
| MX (1) | MXPA01012355A (en) |
| NO (1) | NO20015859L (en) |
| NZ (1) | NZ515744A (en) |
| PE (1) | PE20010212A1 (en) |
| PL (1) | PL352575A1 (en) |
| RU (1) | RU2001135800A (en) |
| SK (1) | SK17012001A3 (en) |
| TR (1) | TR200103476T2 (en) |
| WO (1) | WO2000072870A1 (en) |
| ZA (1) | ZA200109704B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| ES2684475T3 (en) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteins that bind to beta amyloid |
| CN105348387B (en) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | Amyloid beta binding proteins |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| RU2700104C2 (en) | 2014-07-10 | 2019-09-12 | Байоарктик Ньюросайенс Аб | IMPROVED ANTIBODIES BINDING Aβ-PROTOFIBRILS |
| CA3008015A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| AU2017205688C1 (en) | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| CN113423384B (en) | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Dry pharmaceutical formulations of CNP conjugates |
| CN114957438B (en) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126304T2 (en) * | 1990-04-27 | 1997-09-04 | Mcmichael, John, Delanson, N.Y. | METHOD AND COMPOSITION FOR TREATING DISEASES OF THE CNS CAUSED BY ABNORMAL BETA AMYLOID PROTEIN |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 HK HK02106241.2A patent/HK1045938A1/en unknown
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Ceased
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Withdrawn
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0011251A (en) | 2002-03-05 |
| AU5726100A (en) | 2000-12-18 |
| AR024558A1 (en) | 2002-10-16 |
| NO20015859L (en) | 2002-02-01 |
| CA2374897A1 (en) | 2000-12-07 |
| KR20020016813A (en) | 2002-03-06 |
| BG106249A (en) | 2002-08-30 |
| WO2000072870A1 (en) | 2000-12-07 |
| NZ515744A (en) | 2004-04-30 |
| HRP20010901A2 (en) | 2003-04-30 |
| EP1181040A1 (en) | 2002-02-27 |
| TR200103476T2 (en) | 2002-04-22 |
| ZA200109704B (en) | 2003-02-26 |
| CN1353615A (en) | 2002-06-12 |
| NO20015859D0 (en) | 2001-11-30 |
| RU2001135800A (en) | 2003-08-20 |
| IS6182A (en) | 2001-11-29 |
| PL352575A1 (en) | 2003-08-25 |
| MXPA01012355A (en) | 2003-06-24 |
| HK1045938A1 (en) | 2002-12-20 |
| IL146575A0 (en) | 2002-07-25 |
| JP2003519620A (en) | 2003-06-24 |
| EE200100649A (en) | 2003-02-17 |
| CZ20014150A3 (en) | 2002-05-15 |
| SK17012001A3 (en) | 2002-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010212A1 (en) | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM | |
| FI80598B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN ENZYMBEREDNING. | |
| CO5190688A1 (en) | PHARMACEUTICAL FORMS OF ORAL ADMINISTRATION AT LEAST PARTIALLY DELAYED WHOSE ACTIVE SUBSTANCE TRAMADOL IS AT LEAST PARTIALLY IN THE FORM OF A COMPOSITE FORMED IN SITU WITH A 100 MG / ML HYDROSOLUBILITY, AND PROCEDURES FOR PREPARATION | |
| AR024074A1 (en) | ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES. | |
| BR0210721A (en) | Pharmaceutically acceptable compound, salt or ester, method for making a compound, and method for treating a patient having, or preventing the patient from acquiring a disease or condition. | |
| CL2004000782A1 (en) | PARENTERAL PHARMACEUTICAL COMPOSITION THAT INCLUDES (A) PIPERACILLIN, (B) TAZOBACTAMO, AND A CHELATING AMINOCARBOXYLIC ACID, WHICH ALSO CAN CONTAIN A TAMPON, AS CITRATE, AND OPTIONALLY AN AMINOGLYCOSIDE; PROCEDURES FOR PREPARATION; AND USE | |
| ECSP024352A (en) | NEW PHARMACEUTICAL COMPOSITION | |
| ATE284415T1 (en) | MUTATED VARIANT OF INSULIN-LIKE GROWTH FACTOR-I (IGF-I) | |
| ES2162319T3 (en) | USE OF THE CLIOQUINOL CHELATING AGENT FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| BR9914940A (en) | Method to improve the pharmacokinetics of tipranavir | |
| BR0211118A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
| SE0002202D0 (en) | New peptides | |
| AR039857A1 (en) | PREPARATIONS OF A SULFINYL ACETAMIDE | |
| EE200300031A (en) | A method of treating climacteric disorders in women during or after menopause | |
| PA8542901A1 (en) | USE OF (Z) -2-CIANO-3-HYDROXI-BUT-2-ENOIC ACID- (4-TRIFLUOROMETILFENIL) -AMIDA TO TREAT MULTIPLE SCLEROSIS | |
| CO5570658A2 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES | |
| NZ535032A (en) | Lyophilised, stable pharmaceutical composition containing factor VIII, which comprises trisodium citrate, but is devoid of amino acids | |
| FR2647677B1 (en) | NOVEL MICRO-PROTEINS, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW MICRO-PROTEINS | |
| KR970706839A (en) | A pharmaceutical composition comprising growth hormone and isoleucine (A PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND ISOLEUCINE) | |
| AR002018A1 (en) | OPTICALLY ACTIVE BENZOTIEPINE DERIVATIVE; METHOD TO PRODUCE IT; OPTICALLY ACTIVE COMPOUND FOR USE IN SUCH METHOD; DEOSTEOGENESIS PROMOTER, AGENT TO PREVENT OR TREAT BONE DISEASES, PROMOTER FOR THE TREATMENT OF BONE FRACTURE, METHOD OF TREATMENT AND | |
| DE60135996D1 (en) | PEPTIDE COMPOSITIONS FOR THE TREATMENT OF PERIODONTAL DISEASES AND PREVENTION OF SKIN AGING | |
| DE69420145D1 (en) | TREATMENT OF PRECANCELY LESIONS BY MURAMYL PEPTIDES | |
| AU2003277280A8 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease | |
| AR021241A1 (en) | PROTEASE INHIBITORS | |
| CO5160245A1 (en) | ORGANIC COMPOUNDS INHIBITORS OF CYSTEINE PROTEINS, IN PARTICULAR INHIBITORS OF CATEPSIN K OF ARILAMINOALQUILAMIDA, AND ITS PHARMACEUTICAL USE FOR THE TREATMENT OR PROFILAXIS OF DISEASES OR MEDICAL CONDITIONS WHERE THIS IMPLICATES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |